These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 832269)
1. Inhibition of neutrophil chemotaxis by 4-hydroxycyclophosphamide. Gilbert DN; Starr P; Eubanks N Cancer Res; 1977 Feb; 37(2):456-9. PubMed ID: 832269 [TBL] [Abstract][Full Text] [Related]
2. Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysis. Low JE; Borch RF; Sladek NE Cancer Res; 1982 Mar; 42(3):830-7. PubMed ID: 7059981 [TBL] [Abstract][Full Text] [Related]
3. Studies on 4-hydroperoxycyclophosphamide (NSC-181815): a simple preparation method and its application for the synthesis of a new class of "activated" sulfur-containing cyclophosphamide (NSC-26271) derivatives. Peter G; Wagner T; Hohorst HJ Cancer Treat Rep; 1976 Apr; 60(4):429-35. PubMed ID: 1277218 [TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective. Friedman OM; Wodinsky I; Myles A Cancer Treat Rep; 1976 Apr; 60(4):337-46. PubMed ID: 1277209 [TBL] [Abstract][Full Text] [Related]
5. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Sladek NE; Doeden D; Powers JF; Krivit W Cancer Treat Rep; 1984 Oct; 68(10):1247-54. PubMed ID: 6395951 [TBL] [Abstract][Full Text] [Related]
6. Cross-linking of DNA in L1210 cells and nuclei treated with cyclophosphamide and phosphoramide mustard. Surya YA; Rosenfeld JM; Hillcoat BL Cancer Treat Rep; 1978 Jan; 62(1):23-9. PubMed ID: 564237 [TBL] [Abstract][Full Text] [Related]
7. Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite. Struck RF; Kirk MC; Witt MH; Laster WR Biomed Mass Spectrom; 1975 Feb; 2(1):46-52. PubMed ID: 1131393 [TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacologic study in vitro and in vivo with cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and plain nitrogen mustard compounds. Brock N Cancer Treat Rep; 1976 Apr; 60(4):301-8. PubMed ID: 1277205 [TBL] [Abstract][Full Text] [Related]
9. Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy. Jardine I; Fenselau C; Appler M; Kan MN; Brundrett RB; Colvin M Cancer Res; 1978 Feb; 38(2):408-15. PubMed ID: 620410 [TBL] [Abstract][Full Text] [Related]
10. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Dirven HA; van Ommen B; van Bladeren PJ Cancer Res; 1994 Dec; 54(23):6215-20. PubMed ID: 7954469 [TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of human neutrophil chemotaxis to N-formyl-methionyl-leucyl-phenylalanine by sulfones. Harvath L; Yancey KB; Katz SI J Immunol; 1986 Aug; 137(4):1305-11. PubMed ID: 3016092 [TBL] [Abstract][Full Text] [Related]
12. Half-life of oxazaphosphorines in biological fluids. Sladek NE; Powers JF; Grage GM Drug Metab Dispos; 1984; 12(5):553-9. PubMed ID: 6149904 [TBL] [Abstract][Full Text] [Related]
13. Biologic activity of two derivatives and six possible metabolites of cyclophosphamide (NSC-26271). Lelieveld P; van Putten LM Cancer Treat Rep; 1976 Apr; 60(4):373-9. PubMed ID: 1064468 [TBL] [Abstract][Full Text] [Related]
14. Different inhibitory effect of nitrogen mustard (HN2) and TS-160 (HN3) on choline transport in L 5178Y lymphoblasts. Ujházy V; Kolarov J; Kuzela S; Krempaský V; Bohunická E Neoplasma; 1975; 22(6):621-3. PubMed ID: 1240604 [TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity and DNA cross-linking activity of 4-sulfidocyclophosphamides in mouse leukemia cells in vitro. Erickson LC; Ramonas LM; Zaharko DS; Kohn KW Cancer Res; 1980 Nov; 40(11):4216-20. PubMed ID: 7471062 [TBL] [Abstract][Full Text] [Related]
16. [Effect of polydatin on lipopolysaccharide-induced leucocyte chemotaxis]. Huang HX; Zhao Q; Jin CH Di Yi Jun Yi Da Xue Xue Bao; 2003 Dec; 23(12):1253-6. PubMed ID: 14678882 [TBL] [Abstract][Full Text] [Related]
17. Approaches to the pharmacokinetics of cyclophosphamide (NSC 26271): Quantitation of metabolites. Jardine I; Brundrett R; Colvin M; Fenselau C Cancer Treat Rep; 1976 Apr; 60(4):403-8. PubMed ID: 1277214 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of tetracycline in the neutrophil chemotactic response. Majeski JA; Alexander JW J Lab Clin Med; 1977 Aug; 90(2):259-65. PubMed ID: 886211 [TBL] [Abstract][Full Text] [Related]
19. Studies on the selective action of cyclophosphamide (NSC-26271): Inactivation of the hydroxylated metabolite by tissue-soluble enzymes. Cox PJ; Phillips BJ; Thomas P Cancer Treat Rep; 1976 Apr; 60(4):321-6. PubMed ID: 179712 [TBL] [Abstract][Full Text] [Related]
20. Alkylating properties of phosphoramide mustard. Colvin M; Brundrett RB; Kan MN; Jardine I; Fenselau C Cancer Res; 1976 Mar; 36(3):1121-6. PubMed ID: 1253171 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]